全文获取类型
收费全文 | 47750篇 |
免费 | 4371篇 |
国内免费 | 2799篇 |
专业分类
耳鼻咽喉 | 636篇 |
儿科学 | 587篇 |
妇产科学 | 880篇 |
基础医学 | 5306篇 |
口腔科学 | 754篇 |
临床医学 | 5514篇 |
内科学 | 7734篇 |
皮肤病学 | 991篇 |
神经病学 | 2380篇 |
特种医学 | 1695篇 |
外国民族医学 | 18篇 |
外科学 | 4997篇 |
综合类 | 7289篇 |
现状与发展 | 6篇 |
一般理论 | 7篇 |
预防医学 | 3485篇 |
眼科学 | 1034篇 |
药学 | 5145篇 |
39篇 | |
中国医学 | 2436篇 |
肿瘤学 | 3987篇 |
出版年
2024年 | 110篇 |
2023年 | 589篇 |
2022年 | 1450篇 |
2021年 | 1929篇 |
2020年 | 1508篇 |
2019年 | 1467篇 |
2018年 | 1632篇 |
2017年 | 1457篇 |
2016年 | 1381篇 |
2015年 | 2049篇 |
2014年 | 2541篇 |
2013年 | 2538篇 |
2012年 | 3572篇 |
2011年 | 3711篇 |
2010年 | 2530篇 |
2009年 | 2045篇 |
2008年 | 2664篇 |
2007年 | 2644篇 |
2006年 | 2608篇 |
2005年 | 2406篇 |
2004年 | 2084篇 |
2003年 | 2135篇 |
2002年 | 1860篇 |
2001年 | 1429篇 |
2000年 | 1168篇 |
1999年 | 902篇 |
1998年 | 548篇 |
1997年 | 511篇 |
1996年 | 387篇 |
1995年 | 344篇 |
1994年 | 311篇 |
1993年 | 230篇 |
1992年 | 349篇 |
1991年 | 306篇 |
1990年 | 234篇 |
1989年 | 183篇 |
1988年 | 206篇 |
1987年 | 162篇 |
1986年 | 130篇 |
1985年 | 118篇 |
1984年 | 85篇 |
1983年 | 47篇 |
1982年 | 32篇 |
1981年 | 38篇 |
1980年 | 23篇 |
1979年 | 35篇 |
1978年 | 24篇 |
1977年 | 19篇 |
1973年 | 25篇 |
1970年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
<正>慢性阻塞性肺病(chronic obstructive pulmonary diseases,COPD)在临床呼吸科发病率与病死率排名首位,使患者的生命受到严重威胁[1]。COPD患者由于消化、呼吸功衰退,营养吸收功能减弱,同时气道阻力升高,减弱了肺部顺应性,所以伴发能量不足型营养障碍的机率较高[2-3]。出现营养不良的患者往往疾病加重,影响预后,而临床COPD患者疾病严重程度与预后又同肺功能变化密切相关[4]。本文分析了不同营养状况与COPD患者预后的相关性。 相似文献
23.
24.
25.
26.
线粒体脑肌病属于罕见性母系遗传病,本文回顾性分析了1家4例高乳酸血症-卒中样发作综合征(MELAS)型线粒体脑肌病患者,其主要表现为卒中样发作、头痛、癫痫、高乳酸血症、肌肉不耐受疲劳、高级智能下降、听力下降和身材矮小等,结合特征性影像学变化、基因检测及肌肉活检明确诊断,并结合文献对只有女儿能将其线粒体DNA(mt-DNA)传递给下一代的母系遗传MELAS型线粒体脑肌病临床特点进行了总结分析,旨在帮助临床认识此病,进一步提高MELAS型线粒体脑肌病的临床诊断率。 相似文献
27.
Su Jeong Seong Jin Pyo Hong Bong-Jin Hahm Hong Jin Jeon Jee Hoon Sohn Jun Young Lee Maeng Je Cho 《Journal of Korean medical science》2015,30(11):1675-1681
While decreasing trend in gender differences in alcohol use disorders was reported in Western countries, the change in Asian countries is unknown. This study aims to explore the shifts in gender difference in alcohol abuse (AA) and dependence (AD) in Korea. We compared the data from two nation-wide community surveys to evaluate gender differences in lifetime AA and AD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Face-to-face interviews using the Composite International Diagnostic Interview (CIDI) were applied to all subjects in 2001 (n=6,220) and 2011 (n=6,022). Male-to-female ratio of odds was decreased from 6.41 (95% CI, 4.81-8.54) to 4.37 (95% CI, 3.35-5.71) for AA and from 3.75 (95% CI, 2.96-4.75) to 2.40 (95% CI, 1.80-3.19) for AD. Among those aged 18-29, gender gap even became statistically insignificant for AA (OR, 1.59; 95% CI, 0.97-2.63) and AD (OR, 1.18; 95% CI, 0.80-2.41) in 2011. Men generally showed decreased odds for AD (0.55; 95% CI, 0.45-0.67) and women aged 30-39 showed increased odds for AA (2.13; 95% CI 1.18-3.84) in 2011 compared to 2001. Decreased AD in men and increased AA in women seem to contribute to the decrease of gender gap. Increased risk for AA in young women suggests needs for interventions. 相似文献
28.
29.
A. Prado Rodríguez R. Mato Búa L. Mera Mujico J. Arca Suárez M. López Sánchez L. Sampayo Rodríguez P. Rama-Maceiras 《Revista espa?ola de anestesiología y reanimación》2021,68(6):361-366
Serum lactate is a non-specific marker of tissue hypoperfusion. Elevated serum lactate is used in the differential diagnosis of acute intestinal ischemia. Although this practice is controversial, in the absence of other validated markers lactate is still used because of its high sensitivity.We present the cases of two patients who developed acute mesenteric ischemia as a post-surgical complication. The patients reported moderate abdominal pain —a non-specific symptom in the postoperative context— and tests showed progressively increasing serum lactate levels, which facilitated suspicion and subsequent diagnostic confirmation through an imaging test.These cases highlight the physiopathological importance of lactate elevation in the perioperative context and of performing a differential diagnosis of its possible causes, including mesenteric ischemia. Although the outcome was negative in the first case, early suspicion allowed us to make an effective diagnosis and administer appropriate treatment in the second patient. 相似文献
30.
Se-Jin Lee Adam Lehar Yewei Liu Chi Hai Ly Quynh-Mai Pham Michael Michaud Renata Rydzik Daniel W. Youngstrom Michael M. Shen Vesa Kaartinen Emily L. Germain-Lee Thomas A. Rando 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(49):30907
Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit skeletal muscle growth (for review, see ref. 1). Mice lacking MSTN exhibit dramatic increases in muscle mass throughout the body, with individual muscles growing to about twice the normal size (2). MSTN appears to play two distinct roles in regulating muscle size, one to regulate the number of muscle fibers that are formed during development and a second to regulate the growth of those fibers postnatally. The sequence of MSTN has been highly conserved through evolution, with the mature MSTN peptide being identical in species as divergent as humans and turkeys (3). The function of MSTN has also been conserved, and targeted or naturally occurring mutations in MSTN have been shown to cause increased muscling in numerous species, including cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans (12). Numerous pharmaceutical and biotechnology companies have developed biologic agents capable of blocking MSTN activity, and these have been tested in clinical trials for a wide range of indications, including Duchenne and facioscapulohumeral muscular dystrophy, inclusion body myositis, muscle atrophy following falls and hip fracture surgery, age-related sarcopenia, Charcot–Marie–Tooth disease, and cachexia due to chronic obstructive pulmonary disease, end-stage kidney disease, and cancer.The finding that certain inhibitors of MSTN signaling can increase muscle mass even in Mstn−/− mice revealed that the function of MSTN as a negative regulator of muscle mass is partially redundant with at least one other TGF-β family member (13, 14), and subsequent studies have identified activin A as one of these cooperating ligands (15, 16). MSTN and activin A share many key regulatory and signaling components. For example, the activities of both MSTN and activin A can be modulated extracellularly by naturally occurring inhibitory binding proteins, including follistatin (17, 18) and the follistatin-related protein, FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also appear to share receptor components. Based on in vitro studies, MSTN is capable of binding initially to the activin type II receptors, ACVR2 and ACVR2B (also called ActRIIA and ActRIIB) (18) followed by engagement of the type I receptors, ALK4 and ALK5 (21). In previous studies, we presented genetic evidence supporting a role for both ACVR2 and ACVR2B in mediating MSTN signaling and regulating muscle mass in vivo. Specifically, we showed that mice expressing a truncated, dominant-negative form of ACVR2B in skeletal muscle (18) or carrying deletion mutations in Acvr2 and/or Acvr2b (13) have significantly increased muscle mass. One limitation of the latter study, however, was that we could not examine the consequence of complete loss of both receptors using the deletion alleles, as double homozygous mutants die early during embryogenesis (22). Moreover, the roles that the two type I receptors, ALK4 and ALK5, play in regulating MSTN and activin A signaling in muscle in vivo have not yet been documented using genetic approaches. Here, we present the results of studies in which we used floxed alleles for each of the type II and type I receptor genes in order to target these receptors alone and in combination in muscle fibers. We show that these receptors are functionally redundant and that signaling through each of these receptors contributes to the overall control of muscle mass. 相似文献